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S. Taïeb, L. Ceugnart, F. Bonodeau, L. Vanseymortier, A. Adenis The management and the prognosis of gastrointestinal stromal tumors (GIST) have evolved rapidly with new targeted treatments. The aim of this paper is to assess the role of imaging not only for diagnosis but to quantify treatment response. RECIST criteria, which are the standard in assessment of post chemotherapy response in adult's solid tumors, can not be used in targeted therapy: the changes in lesion structures even if case of increasing volume are more specific to assess tumor response.